SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:5c1b844f-e3c8-4584-ae86-e6824192d7d4"
 

Search: onr:"swepub:oai:lup.lub.lu.se:5c1b844f-e3c8-4584-ae86-e6824192d7d4" > Lentivirus-Induced ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Sundarasetty, Bala Sai (author)

Lentivirus-Induced Dendritic Cells for Immunization Against High-Risk WT1(+) Acute Myeloid Leukemia

  • Article/chapterEnglish2013

Publisher, publication year, extent ...

  • Mary Ann Liebert Inc,2013

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:5c1b844f-e3c8-4584-ae86-e6824192d7d4
  • https://lup.lub.lu.se/record/3674603URI
  • https://doi.org/10.1089/hum.2012.128DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Wilms' tumor 1 antigen (WT1) is overexpressed in acute myeloid leukemia (AML), a high-risk neoplasm warranting development of novel immunotherapeutic approaches. Unfortunately, clinical immunotherapeutic use of WT1 peptides against AML has been inconclusive. With the rationale of stimulating multiantigenic responses against WT1, we genetically programmed long-lasting dendritic cells capable of producing and processing endogenous WT1 epitopes. A tricistronic lentiviral vector co-expressing a truncated form of WT1 (lacking the DNA-binding domain), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-4 (IL-4) was used to transduce human monocytes ex vivo. Overnight transduction induced self-differentiation of monocytes into immunophenotypically stable "SmartDC/tWT1" (GM-CSF+, IL-4(+), tWT1(+), IL-6(+), IL-8(+), TNF-alpha(+), MCP-1(+), HLA-DR+, CD86(+), CCR2(+), CCR5(+)) that were viable for 3 weeks in vitro. SmartDC/tWT1 were produced with peripheral blood mononuclear cells (PBMC) obtained from an FLT3-ITD+ AML patient and surplus material from a donor lymphocyte infusion (DLI) and used to expand CD8(+) T cells in vitro. Expanded cytotoxic T lymphocytes (CTLs) showed antigen-specific reactivity against WT1 and against WT1(+) leukemia cells. SmartDC/tWT1 injected s.c. into Nod.Rag1(-/-).IL2r gamma c(-/-) mice were viable in vivo for more than three weeks. Migration of human T cells (huCTLs) to the immunization site was demonstrated following adoptive transfer of huCTLs into mice immunized with SmartDC/tWT1. Furthermore, SmartDC/tWT1 immunization plus adoptive transfer of T cells reactive against WT1 into mice resulted in growth arrest of a WT1(+) tumor. Gene array analyses of SmartDC/tWT1 demonstrated upregulation of several genes related to innate immunity. Thus, SmartDC/tWT1 can be produced in a single day of ex vivo gene transfer, are highly viable in vivo, and have great potential for use as immunotherapy against malignant transformation overexpressing WT1.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Singh, Vijay Kumar (author)
  • Salguero, Gustavo (author)
  • Geffers, Robert (author)
  • Rickmann, Mareike (author)
  • Macke, Laura (author)
  • Borchers, Sylvia (author)
  • Figueiredo, Constanca (author)
  • Schambach, Axel (author)
  • Gullberg, UrbanLund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine(Swepub:lu)efor-ugu (author)
  • Provasi, Elena (author)
  • Bonini, Chiara (author)
  • Ganser, Arnold (author)
  • Woelfel, Thomas (author)
  • Stripecke, Renata (author)
  • Avdelningen för hematologi och transfusionsmedicinInstitutionen för laboratoriemedicin (creator_code:org_t)

Related titles

  • In:Human Gene Therapy: Mary Ann Liebert Inc24:2, s. 220-2371043-03421557-7422

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view